NEW YORK – Syros Pharmaceuticals said on Tuesday that its retinoic acid receptor-alpha agonist tamibarotene, which it was testing in combination with azacitidine in patients newly diagnosed with ...

Syros Pharmaceuticals’ blood cancer prospect tamibarotene has failed another study, triggering a default on a loan and wiping ...

Syros Pharmaceuticals Inc (NASDAQ:SYRS) is advancing tamibarotene as a potential new standard of care for higher-risk MDS patients with RARA overexpression, targeting a significant unmet medical need.

Syros Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.16, expectations were $-0.72. Operator: Good morning, and welcome to the Syros Pharmaceuticals Third Quarter 2024 ...

TD Cowen analyst Phil Nadeau has maintained their bullish stance on SYRS stock, giving a Buy rating today. Phil Nadeau has given his Buy ...

Good morning, and welcome to the Syros Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Note that this call is being ...

CAMBRIDGE, Mass., October 31, 2024--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of ...

Cruise Critic is not a booking agent and does not charge any service fees to users of our site. Our partners who list cruise pricing on Cruise Critic are required to provide prices for cruise only ...

If you are in the market for a new car, we can help you find the best new car deals and the latest incentives from car dealers in your area.

The current knowledge on the herpetofauna of Syros is updated, whereby no publications on it have been made since 1975. I provide the results from a field trip in 2024 that focused on the hygrophilous ...

The Bishop of Syros and Catholic priests are implicated in a serious financial corruption scandal, as €3 million from the Greek Catholic Church’s funds were allegedly funneled into accounts of ...